The Effect of the Nutraceutical "Hemofix" on the Coagulation System
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01651468 |
Recruitment Status :
Withdrawn
(The collaborator lost interest in a clinical study.)
First Posted : July 27, 2012
Last Update Posted : November 28, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Von Willebrand Disease Menorrhagia | Dietary Supplement: HEMOFIX | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System |
Study Start Date : | September 2016 |
Estimated Primary Completion Date : | January 2020 |
Estimated Study Completion Date : | December 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: HEMOFIX
3 grams a day
|
Dietary Supplement: HEMOFIX
unique complex herbal mixture |
- bleeding and blood test results [ Time Frame: one year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteers and volunteers with a mild bleeding disorder
Exclusion Criteria:
- people with thrombophilic and cardiovascular complications,
- people who are treated with anti-coagulants,
- women taking birth control pills
- people with a history hypercoagulability

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01651468
Israel | |
Hadassah Medical Organization | |
Jerusalem, Israel |
Principal Investigator: | David Varon, Prof | HMO |
Responsible Party: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT01651468 |
Other Study ID Numbers: |
HEMOFIX- HMO-CTIL |
First Posted: | July 27, 2012 Key Record Dates |
Last Update Posted: | November 28, 2017 |
Last Verified: | February 2017 |
mild bleeding disorder |
Menorrhagia Von Willebrand Diseases Uterine Hemorrhage Uterine Diseases Hemorrhage Pathologic Processes Menstruation Disturbances |
Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Blood Platelet Disorders Hemorrhagic Disorders Genetic Diseases, Inborn |